The latter structures turned out to be more effective as H. pylori binders than the parent saccharide. New reducingend variants of the neolacto epitope including species containing N-acetyllactosamine linked β6 to GlcNAc or Gal with similarity to branched polylactosamines and mucins were prepared and tested. The results extend our previous findings on binding specificities of H. pylori and show that this pathogen is able to interact with an array of N-acetyllactosamine/neolacto structures, which may be of importance for the in vivo interaction of the bacterium with human cells. The information gained in this work may also be of value for rational design of anti-H. pylori drugs.
Introduction
Helicobacter pylori is a common human gastric pathogen associated with chronic gastritis and duodenal and gastric ulcers (Dunn et al. 1997; McGee and Mobley 1999; Figueiredo et al. 2005) . The infection increases the risk of neoplastic diseases of the gastrointestinal tract (Peek and Blaser 2002; Marshall and Windsor 2005; Fuccio et al. 2007) , and in 1994, the bacterium was classified by the World Health Organization as a class 1 carcinogen (IARC 1994) . Like many other microbes, H. pylori has the ability to adhere to cell surfaces of target tissues, and the binding is mediated by host carbohydrates (Karlsson 2000) . Table I shows saccharide structures which are known to bind the bacterium. The significance of the multiple binding specificities is at present not clear. Lewis b epitope (Van de Bovenkamp et al. 2003) , sulfated structures (Natomi et al. 1993) , and lacto epitope (Teneberg et al. 2002) were found in the stomach epithelium and are believed to be of importance for colonizanion. Neu5Ac may also have an important role since H. pylori-induced inflammation is associated with higher expression of this monosaccharide in the mucosa layer (Syder et al. 1999; Chaturvedi et al. 2001; Mahdavi et al. 2002) . Neu5Ac and neolacto saccharides are also present in human neutrophils (Fukuda et al. 1985; Muthing et al. 1996; Stroud et al. 1996; Miller-Podraza et al. 1999 ) and human saliva (Prakobphol et al. 1998 ; Thompson et al. 2002) , which are of relevance for the maintance of chronic H. pylori inflammations in the stomach (Blaser 1992; Karlsson 2000) and for binding of H. pylori in the oral cavity. Nonsialylated neolacto structures have not yet been found as binding epitopes in the stomach mucosa. However, they are expected to be present in this tissue because the mucosa layer contains a wide range of complex glycoproteins including highly glycosylated mucins and proteoglycans.
H. pylori can be eradicated from the stomach using antibiotics. However, this treatment may lead to development of antibiotic resistance and is not recommended for prevention. Knowledge about binding specificities of H. pylori and detailed information on binding epitopes may be of importance for development of antiadhesion therapy (Karlsson 2000) .
Results
In a previous paper, we described binding of H. pylori to various neutral neolacto-based glycolipid sequences, and the minimum epitope was proposed to be GlcNAcβ3Galβ4 GlcNAcβ . In the present paper, we report two new neolacto nonsialylated compounds with binding activity with the terminal trisaccharide GlcAβ3Galβ4 GlcNAcβ3 and Glcβ3Galβ4GlcNAcβ3 (Nos. 1 and 2 in Table II ), respectively. Binding of H. pylori to GlcAβ3Galβ4GlcNAcβ 3Galβ4Glcβ1Cer and its reduced counterpart Glcβ3Galβ4Glc NAcβ3Galβ4Glcβ1Cer is shown in Figures 1 and 2B . Both glycolipids were active; howewer, the detection level was higher for the GlcA-containing variant indicating lower affinity for the bacterium. Interestingly, amidation of GlcA could improve the binding. N-Methyl-and N-ethyl-amides of the GlcAβ 3Galβ4GlcNAcβ3Galβ4Glcβ1Cer (Nos. 3 and 4 in Table II) turned out to be more potent than the parent glycolipid. The Miller-Podraza et al. 1996; Evans et al. 1988; Slomiany et al. 1989; Hirmo et al. 1996 Hirmo et al. , 1998 Mahdavi et al. 2002 ) Some blood group antigens, e.g. Lewis b antigen Fucα2Galβ3(Fucα4)GlcNAcβ-R (Lewis b) (Borén et al. 1993) Ganglio structures Galβ3GalNAcβ4Galβ4Glcβ1Cer GalNAcβ4Galβ4Glcβ1Cer (Lingwood et al. 1992) Some sulfated structures HSO 3 -R (Slomiany et al. 1989; Ascencio et al. 1993; Natomi et al. 1993) binding by H. pylori of these amides was on TLC plates about 20 times stronger than that of the unmodified glycolipid ( Figure 2A ). The detection level for N-methyl-and N-ethyl-amides was between 10 and 50 pmol per spot which is similar to detection levels of the most potent previously described glycolipids (Miller-Podraza et al. 2004 , 2005 Johansson et al. 2005) . Structures and MS data of the new neolacto-based epitopes are shown in Figures 3 and 4 and Table III . We also investigated the importance of GlcNAcs and N-acetamido groups by binding of H. pylori to de-N-acetylated variants of the Galβ4GlcNAcβ3Galβ4GlcNAcβ3Galβ4Glcβ 1Cer. As shown in Table II (Nos. 8 and 9), the modified structures were inactive indicating that N-acetylation is crucial for the interaction with H. pylori. Negative binding results were also obtained when the ring of the terminal Gal of Galβ4GlcNAcβ3Galβ4GlcNAcβ3Galβ4Glcβ1Cer was opened by periodate oxidation (Table II , No. 7, and Figure 5 ). In the latter experiment, the aldehyde groups generated in the molecule by NaIO 4 were reduced to alcohols. The experiment confirmed that a modified neighboring group may restrict access to the GlcNAcβ3Galβ4GlcNAcβ.
Binding experiments in this work were performed on both glycosphingolipids and their derivatives (Table II) and neoglycolipids (Table IV) . The latter were prepared by chemical coupling of free neolacto oligosacharides to selected aminated lipids. Using neoglycolipids, we could confirm that Table II . Binding activity of carbohydrate structures investigated in this work
Structure
Obtained from Chemical derivatization Binding
None (prepared from rabbit thymus) ++ 7. Gal(oxid/red)β4GlcNAcβ3Galβ4GlcNAcβ3Galβ4Glcβ1Cer 6 R-Gal → R-C 5 O 4 H 11 − 8.Mixture of: Galβ4GlcNβ3Galβ4GlcNAcβ3Galβ4Glcβ1Cer and Galβ4GlcNAcβ3Galβ4GlcNβ3Galβ4Glcβ1Cer
"+++" means strong binding (detection level on TLC plates between 10 and 60 pmol/spot or 1-6 pmol/mm 2 ). "++" and "+" mean less strong bindings (60-200 pmol/spot and more on TLC plates). "−" means no binding on TLC plates. The modified monosaccharides are underlined. neolacto structures carrying terminal GlcNAc or GlcAMe (methyl amide of GlcA) are among the best binders, which is in agreement with the results obtained from experiments performed on natural glycolipids and their derivatives (compare with Table II ). Neoglycolipids carrying terminal GlcA displayed lower binding strength as compared to other neolacto-based neoglycolipid variants, which also is in line with studies performed on ceramide-based glycolipids. Studies using neoglycolipids also confirmed the importance of more distal sugars for the binding. As shown, active epitopes were influenced by subtle changes in the core chain. The glycolipids were most active when the trisaccharide epitope was coupled to GlcNAc or Gal by the β6-linkage (Table IV, Nos. 1, 4, and 7). Further, the replacement of the β6-linkage by α6-or β3-linkage negatively influenced the binding (Table IV, Nos. 2 and 8). Even lipid parts were important, as shown by the use of neoglycolipids containing different hydrophobic moieties (see differences in binding between HDA and C42 derivatives of Neoglycolipid Binding
+++ means binding at the lower pmol level (10-60 pmol/spot) and high frequency of binding. + + and + mean less strong bindings. (+) means occasional binding. HDA, hexadecylaniline.C42, palmitate-lysine-based branched lipid with 42 carbon atoms. Table IV ). An example of mass spectrometry of neoglycolipids is shown in Figure 6 .
Discussion
In a previous paper, we reported a new binding specificity of H. pylori based on nonsialylated neolacto carbohydrate chains . GlcNAcβ3Galβ4GlcNAcβ3Galβ4 Glc-β1Cer is an effective binder of the bacterium on TLC plates and we have proven that the terminal GlcNAcβ3 of this glycolipid can be replaced by GalNAcβ3 (part of X-2 epitope), GalNAcα3 (part of A-antigen), or Galα3 (part of B antigen/xenoantigen) without the loss of the activity. In the present paper, we report new neolacto-based pentaglycosylceramides with binding activity for H. pylori, carrying GlcAβ, Glcβ, GlcA(-CO-N-Me), and GlcA(-CO-N-Et) as a terminal monosacharide (Table II and Figures 1-4) , respectively. These structures broaden the spectrum of neolacto epitopes recognized by H. pylori. The specificity includes two different epimers at C4 (Gal-resp. Glc) and possibly N-acetyl substituent at C2, as well as tolerance of both α-and β-linkages ). Similar specificity was described for Clostridium difficile toxin A and Galα3-xenoantibodies (Teneberg et al. 1996) . The Glcβ3 terminal has not yet been found on natural neolacto glycans; however, the terminal GlcAβ3 is part of HNK-1 epitope precursors present on natural killer (NK) cells. Terminal GlcAβ3Galβ4GlcNAc is part of the HNK-1 epitope which carries a sulfate ester at 3-position of the glucuronic acid. The precursor of the HNK-1 epitope may be a rare natural glycoform. It has been shown that a nonsulfated form of the HNK-1 is present in mouse kidney (Tagawa et al. 2005) , and it has been suggested that the sulfated epitope is partially replaceable in carbohydrate-protein interactions by a nonsulfated precursor (Chou et al. 2002) . It should be noted that H. pylori has been reported to interact with NK cells (Tarkkanen et al. 1993; Kuo et al. 2005; Yun et al. 2005) . The potential role of HNK-1 precursors in microbial interactions requires however further studies. Chemical or enzymatic synthesis using cloning techniques as well as characterization of the biosynthetic enzymes could contribute to the in vitro production of rare HNK-1 variants for further investigation of host-pathogen interactions (Terayama et al. 1997; Kornilov et al. 2000; Ong et al. 2002; Kizuka et al. 2006 ).
The results show that H. pylori has the ability to interact with a wide range of terminal carbohydrate structures associated with neolacto core chains. Galβ4GlcNAcβ3Galβ4GlcNAc is a common component of human cells. However, other neolacto-based structures discussed in this paper have not yet been described as regular parts of carbohydrates in human stomach or other potential H. pylori target tissues. It is not likely that they serve as natural binding epitopes for the bacterium. On the other hand, some inner sequences of carbohydrate chains present in the gastric mucosa and other glyco components of human cells and body fluids can be identical or resemble these structures and can be of importance for the interaction with H. pylori. As previously discussed , GlcNAcβ3Galβ4GlcNAc is present as an internal sequence in neolacto carbohydrate chains with repeated N-acetyllactosamine units and occurs in various carbohydrate chains of complex glycoproteins, glycolipids, and glycosaminoglycans.
Several research groups have indicated gastric mucins as binding sites for H. pylori (Hirmo et al. 1998 ; Van de Bovenkamp et al. 2003) . MUC5Ac has been proposed as the main receptor for the bacterium in the stomach (Van de Bovenkamp et al. 2003) , and the Lewis b antigen has been pointed out as a binding part of this protein (Linden et al. 2002) . However, H. pylori can bind to epithelial cells in the absence of the Lewis b epitope (Rubinsztein-Dunlop et al. 2005) indicating that other sequences are also involved in the binding (Linden et al. 2004) . Experiments with neoglycolipids (Table IV) reveal that the terminal neolacto-type epitope structures linked by β6-linkages to Gal/GlcNAc have a high binding activity. This implies that GlcNAcβ3Galβ4GlcNAcβ6GalNAc of human gastric mucin (Hanisch et al. 1993 ) may be a potential mucosal receptor for H. pylori. Neolacto-based structures may also be of importance, together with other epitopes, for the interaction with H. pylori in the oral cavity. It has been proposed that mucins MG1 and MG2, which are present in human saliva, bind H. pylori through sialyl-Lewis x, Lewis b, and sialyl-Lewis a epitopes (Prakobphol et al. 2005 ). MG1 and MG2 contain a variety of structures based on lacto, neolacto, and GalNAc-containing carbohydrate chains, creating an enormous repertoire of potential binding sites for microorganisms (Prakobphol et al. 1998; Thompson et al. 2002) .
It should be noted that gastric mucosa layer contains heparan sulfate, dermatan sulfate, and hyaluronic acid (Theocharis et al. 2003) and glycosaminoglycans made up of hexoses, hexosamines, and uronic acids. Hexoses, hexosamines, and an uronic acid (glucuronoic acid, GlcA) are also present in carbohydrate epitopes discussed in this paper. It is possible that H. pylori binds to proteoglycans present in human stomach which is supported by studies on binding of H. pylori to chondroitin sulfate (Linden et al. 2004 ) and heparan sulfate (Ascencio et al. 1993) .
On the other hand, we know that not all neolacto-based saccharides are recognized by H. pylori and that particular side groups and vicinal sugars may hamper the activity. Previously we have shown, using a large number of carbohydrate structures, that the only terminal extentions of the GlcNAcβ3Galβ4GlcNAc epitope which are tolerated by the bacterium are Galβ4 and NeuAcα3Galβ4 . In the present study, we have shown that oxidized/reduced Galβ4GlcNAc β3Galβ4GlcNAcβ3Galβ4Glcβ1Cer also is inactive as a binding molecule (Table II , No. 7 and Figure 5 ). Using periodate oxidation followed by reduction with NaBH 4 , we could open the terminal Gal ring without modification of other sugars, leaving the internal GlcNAcβ3Galβ4GlcNAcβ intact. Various de-N-acetylated variants of Galβ4GlcNAcβ3Galβ4GlcNAcβ3 Galβ4Glcβ1Cer (Table II , Nos. 8 and 9) were also inactive indicating that the intact core chain of GlcNAcs is required.
Using neoglycolipids with different carbohydrate core structures, we have further confirmed the importance of distal monosacharides in more extended chains. We have shown that both glycosidic linkages and types of monosaccharides are of importance for the interaction (Table IV) . It seems that structural conditions required for optimal interactions of H. pylori with carbohydrate sequences on TLC plates are defined by both binding areas (actual epitopes) and carrier parts of the molecules. We have previously examined the role of GlcNAc in NeuAcα3Galβ4GlcNAcβ-R for H. pylori binding (Johansson et al. 2005 ) and came to the conclusion that this monosacharide is of importance for spatial orientation of the epitope. The hydrophobic layers of TLC plates mimic natural conditions of cell surfaces, and one may speculate that saccharide core chains as well as aglycons could be of importance for the in vivo adhesion of H. pylori.
Because of the shortage and hydrophobic nature of chemical derivatives used in this work, the binding experiments were limited to TLC overlay tests. TLC binding assays are proper for work with small amounts of lipid substances, both pure and in mixtures, and in a previous paper we have confirmed the reliability of TLC overlay assays in H. pylori studies comparing this approach with hemagglutination inhibition assay and another binding assay based on the use of carbohydrate epitopes in water milieu (Johansson et al. 2005) . The TLC method is an excellent approach for the survey of activities; however, the results should be considered as semi-quantitative, and further investigation of selected molecules is necessary.
As discussed, the use of antibiotics is not recommended for the prevention of H. pylori diseases in large human populations because resistant strains are emerging (Van Der Wouden et al. 2000; Wu et al. 2005 ). However, anti-H. pylori therapy is rational and effective for patients with developed disease (Pilotto and Malfertheiner 2002; Ford et al. 2004; Bytzer 2005) . Regarding potential anti-adhesion therapy, the best effects may be obtained using mixtures of molecules with different active epitopes including natural molecules and their analogs. Novel glycan libraries from chemo/enzymatic synthesis, as presented here, as well as novel array technologies open a new era for studies of pathogen-host interactions and screening of pharmaceuticals against infections (Disney and Seeberger 2004; Stevens et al. 2006 ).
Material and methods

Preparation of glycolipid derivatives Glcβ3Galβ4GlcNAcβ3Galβ4Glcβ1Cer (Table II, No. 2).
This structure was prepared from GlcAβ3Galβ4GlcNAc β3Galβ4Glcβ1Cer (glucuronylneolactotetraosylceramide, 18, 18, Wako Pure Chemical Industries) (Table II, No. 1), by reduction of R-COOH to RCH 2 OH. The glycolipid (100 μg) was dissolved in DMSO (250 μL, Fluka/Sigma-Aldrich, Sweden), mixed with CH 3 I (50 μL, Fluka, Steinheim, Germany), and sonicated at room temperature for 1 h, followed by freeze drying. The produced methyl ester was dissolved in 300 μL of methanol and incubated at room temperature in the presence of 4 mg of NaBH 4 overnight. The sample was next evaporated, dissolved in 2 mL of C/M/H 2 O (60:30:4.5), and desalted using a small column filled with Sephadex G-25 . The yield of the derivatization was about 50%, as estimated by TLC chromatography using as a developing solvent C/M/0.25%KCl in H 2 O (50:40:10, by vol). Finally, the material was separated by phase partition using the Folch's system (Folch et al. 1957 ), C/M/H 2 O (8:4:3), and Glcβ3Galβ4GlcNAcβ3Galβ4Glcβ1Cer was recovered from the lower phase.
Amide forms prepared from GlcAβ3Galβ4GlcNAcβ3Galβ4Glcβ1Cer
Methyl Amide (Table II, No. 3). Hundred micrograms of the parent glycolipid was converted to methyl ester using CH 3 I as described above, freeze dried, dissolved in 500 μL of methanol, and mixed with 500 μL of 40% of methylamine (Fluka/SigmaAldrich, Sweden) in water. The sample was incubated at room temperature overnight and evaporated under nitrogen. (Table II , Nos. 4 and 5). One hundred and forty micrograms of GlcAβ3Galβ4GlcNAc β3Galβ4Glcβ1Cer was converted to the methyl ester form as described above and divided into two portions (samples 1 and 2). Each sample was dissolved in 500 μL of methanol, and the amidation was induced by adding 1 mL of ethylamine (Aldrich Chemical Company, Steinheim, Germany) or 100 μL of benzylamine (Fluka/Sigma-Aldrich, Sweden) to samples 1 and 2, respectively. The samples were then incubated at room temperature overnight, evaporated under nitrogen, and purified on small (Pasteur pipette) silica gel columns using the elution mixtures of organic solvents with increasing polarity (C/M, 2:1; C/M, 1:1; C/M/H 2 O, 60:35:8). The eluates were collected, evaporated, and tested for the presence of sugars using TLC plates (by spotting and dyeing with anisaldehyde). The glycolipid material was collected and used for further analysis.
Ethyl and Benzyl Amides
Galβ4GlcNAcβ3Galβ4GlcNAcβ3Galβ4Glcβ1Cer Derivatives.
Galβ4GlcNAcβ3Galβ4GlcNAcβ3Galβ4Glcβ1Cer (Table II, No. 6) was prepared from rabbit thymus as described . Opening of the terminal Gal (see Table II , No. 7) was performed by periodate oxidation. Galβ4GlcNAcβ3Galβ4GlcNAcβ3Galβ4Glcβ1Cer (200 μg) was dissolved in 400 μL of C/M/0.2 M acetate buffer, pH 4.94, 37:52:18. To this solution, 400 μL of 0.03 M NaIO 4 in C/M/0.2 M acetate buffer, pH 4.94, 16:70:24 was added, and the sample was incubated at room temperature for 6 h. To improve the solubility of the reagents, 100 μL of chloroform was added to the mixture. The oxidation was terminated by the addition of an excess of Na 2 SO 3 . The sample was then evaporated and the material reduced overnight using excess of NaBH 4 . Finally, the glycolipid was desalted by a small G25 column run in organic solvents (Miller-Podraza et al. 2004) .
De-N-acetylation of Galβ4GlcNAcβ3Galβ4GlcNAcβ3Galβ 4Glcβ1Cer was performed as described before (Johansson et al. 2005) . Mono-and di-de-N-acetylated variants of the glycolipid (Table II , Nos. 8 and 9) were analyzed in a mixture of products.
Synthesis of neoglycolipids
Neoglycolipids were synthesized by reductive amination using two kinds of aminated lipids: (a) Hexadecylaniline (Aldrich Chemical Company, Milwaukee, USA), CH 3 (CH 2 ) 15 C 6 H 4 NH 2 , HDA and (b) a branched palmitate-lysine-based conjugate, PalLys(Pal)CONH(CH 2 ) 4 -NH 2 (called later C42) obtained through custom synthesis (RAPP Polymere GmbH, Germany). The core structure of this lipid was made up of palmitic acid (Pal) and lysine (Lys). The conditions for coupling of HDA to free oligosaccharides were as described before (Miller-Podraza et al. 2004 ). The conditions for coupling of C42 to reducing sugars were in a typical experiment as follows. A free oligosacharide (200-600 nmol in 300 μL of M/H 2 O, 2:1) was mixed with C42 (20 mg/mL in C/M, 5:1, 280 μL) and NaBH 3 CN (62 mg/mL in MeOH, 100 μL) (Fluka/Sigma-Aldrich, Sweden), and the sample was kept at 50
• C for 1-2 days. The progress of the reaction was monitored by TLC chromatography using as a developing solvent C/M/0.25% KCl in H 2 O, 50:40:10. The final yield of the products varied between 30% and 70%. The samples were then evaporated, redissolved in a small volume of C/M/H 2 O, 60:30:4.5, and mixed with 10 volumes of C/M 3:1. Each sample was applied on a small (Pasteur pipette) silica gel 60 column. The material was eluted using solvents with increasing polarity: C/M, 2:1; CM, 1:1; C/M/H 2 O, 60:35:8; and C/M/H 2 O, 50:40:10. The eluates were evaporated, redissolved in small volumes of the respective solvents, and tested for the presence of neoglycolipids using the silica gel TLC chromatography as above. The material was collected and used for further analyses.
Synthesis of oligosaccharides
Galβ4GlcNAcβ6GlcNAc. GlcNAcβ6GlcNAc was prepared by HF-reversion of N-acetylglucosamine (Defaye et al. 1989) and isolated by gel filtration chromatography on a column of Superdex 30 (5 × 95 cm). The disaccharide was then β4-galactosylated by bovine milk β4-galactosyltransferase (Calbiochem) (Brew et al. 1968 ). The title trisaccharide was isolated in pure form by chromatography on a column of graphitized carbon (Hypercarb, Thermo-Hypersil Ltd, UK) using for elution gradient 1 (see chromatographic methods below) and characterized by MALDI-TOF MS and 1 H-NMR spectroscopy.
GlcNAcβ3Galβ4GlcNAcβ6GlcNAc. Galβ4GlcNAcβ6GlcNAc obtained as above was incubated with UDP-GlcNAc and human serum containing a β3-GlcNAc transferase essentially as described previously (Piller and Cartron 1983) . The reaction mixture was desalted and deproteinized by passing through a mixed bed column of AG 1-X8 (Ac − ) and AG 50W-X8 (H + ) resins (200-400 mesh, Bio-Rad). The tetrasaccharide was finally isolated by chromatography on a column of graphitized carbon (Hypercarb) using gradient 2 (see chromatographic methods below) and characterized by MALDI-TOF MS and 1 H-NMR spectroscopy.
GlcNAcβ3Galβ4GlcNAcα6GlcNAc. GlcNAcα6GlcNAc was prepared by HCl-reversion of N-acetylglucosamine (Blumberg et al. 1982) followed by β4-galactosylation and β3-GlcNAc transferase reactions as above. The title tetrasaccharide was isolated in pure form by Hypercarb chromatography using gradient 1 and characterized by MALDI-TOF MS and 1 H-NMR spectroscopy.
Neolacto binding by H. pylori
GlcNAcβ3Galβ4GlcNAcβ3Man. GlcNAcβ3Man (Sigma) was β4-galactosylated by bovine milk β4-galactosyltransferase as described above. A crude oligosaccharide fraction was isolated by gel filtration chromatography on a column of Superdex Peptide and subjected to β3-N-acetylglucosaminylation using human serum. The serum reaction mixture was desalted and deproteinized by passing through a mixed bed column of AG 1-X8 (Ac − ) and AG 50W-X8 (H + ) resins. The title tetrasaccharide was isolated by Hypercarb chromatography with gradient 1 and characterized by MALDI-TOF MS and 1 H-NMR spectroscopy.
GlcNAcβ3Galβ4GlcNAcβ6Gal. GlcNAcβ6Gal (Sigma) was β4-galactosylated by bovine milk β4-galactosyltransferase as described above. A crude oligosaccharide fraction was isolated by gel filtration chromatography on a column of Superdex Peptide and subjected to human serum β3-GlcNAc transferase as above. The serum reaction mixture was desalted and deproteinized by passing through a mixed bed column of AG 1-X8 (Ac − ) and AG 50W-X8 (H + ) resins. The title tetrasaccharide was isolated by Hypercarb chromatography with gradient 1 and characterized by MALDI-TOF MS and 1 H-NMR spectroscopy.
GlcAβ3Galβ4GlcNAcβ6GlcNAc. Galβ4GlcNAcβ6GlcNAc obtained as above was subjected to β-glucuronylation using β-glucuronidase transglycosylation reaction essentially as described previously (Yasukochi et al. 1997) . Excessive nitrophenol was removed by solid-phase extraction with BondElut C-18 columns (Varian), and the oligosaccharide products were isolated by gel filtration chromatography on a column of Superdex 30 (5 × 95 cm). The title tetrasaccharide was isolated in pure form by ion-exchange chromatography with ResourceQ and characterized by MALDI-TOF MS and 1 H-NMR spectroscopy.
GlcAβ3Galβ4GlcNAcβ3Galβ4Glc. Galβ4GlcNAcβ3Galβ4Glc (IsoSep, Lund, Sweden) was subjected to glucuronylation using glucuronidase transglycosylation reaction essentially as above. The oligosaccharide products were isolated by gel filtration chromatography on a column of Superdex 30 (5 × 95 cm). The title pentasaccharide was isolated in pure form by ion-exchange chromatography with ResourceQ and characterized by MALDI-TOF MS and 1 H-NMR spectroscopy.
GlcA(N-Me)β3Galβ4GlcNAcβ6GlcNAc. GlcAβ3Galβ4GlcNA cβ6GlcNAc obtained as described above was dissolved in 90% aqueous pyridine containing 3× molar excess of methylamine, HBTU (Novabiochem) and diisopropylethylamine (Fluka). The reaction was conducted at room temperature for 3 days, and the crude oligosaccharide fraction was isolated by gel filtration chromatography on Superdex Peptide. The methylamidated species were isolated by anion-exchange chromatography (neutral fraction), further purified by gel filtration chromatography, and characterized by MALDI-TOF MS and 1 H-NMR spectroscopy.
GlcA(N-Me)β3Galβ4GlcNAcβ3Galβ4Glc. GlcAβ3Galβ4Glc NAcβ3Galβ4Glc was amidated with methylamine in a reaction containing HBTU and diisopropylethylamine as above. The methylamidated species were isolated by anion-exchange chromatography (neutral fraction), further purified by gel filtration chromatography, and characterized by MALDI-TOF MS and 1 H-NMR spectroscopy.
Chromatographic methods
Gel filtration chromatography was performed with Superdex TM Peptide HR 10/30 (10-300 mm) (Amersham Pharmacia Biotech, Sweden) with 50 mM NH 4 HCO 3 as eluent, at a flow rate of 1 mL/min or with Superdex 30 (5 × 95 cm) (Amersham Pharmacia Biotech, Sweden), with 50 mM NH 4 HCO 3 as eluent, at a flow rate of 5 mL/min. All experiments were monitored at 214 nm. Fractions of 10 mL were collected in Superdex 30 runs, while product peaks from the Superdex peptide column were collected manually. Chromatography on graphitized carbon was performed using a Hypercarb column (5 μm, 250 × 4.6 mm; Thermo-Hypersil Ltd, UK). Ammonia was used in the solvents to catalyze mutarotation since separations of the anomeric forms of oligosaccharides were often observed. Two different gradients were employed. Gradient 1: the column was equilibrated with 10 mM NH 3 , and elution was performed with a linear gradient of acetonitrile (0-40% over 60 min). Gradient 2: the column was equilibrated with 10 mM NH 3 , and elution was performed with a linear gradient of acetonitrile (8-40% over 80 min). Absorbance at 214 nm was recorded.
Anion-exchange chromatography was performed on a column of Resource TM Q (Amersham Pharmacia Biotech AB, Sweden). The column was eluted with water for 4 min, and then with a linear gradient of 0-50 mM NaCl over 8 min, followed by a steeper linear gradient of 50 -500 mM NaCl over 8 min. Absorbance at 214 nm was recorded.
Mass spectrometry MALDI-TOF mass spectra of oligosaccharides were recorded on a Voyager-DE TM STR BioSpectrometry TM (PerSeptive Biosystems) time-of-flight instrument. Samples were analyzed in either positive-ion delayed extraction mode using 2,5-dihydroxybenzoic acid (DHB) (Aldrich) matrix (10 mg/mL in H 2 O) or in negative-ion linear delayed extraction mode using 2,4,6-trihydroxyacetophenone (Fluka) (3 mg/mL in acetonitrile/20 mM aqueous diammonium citrate, 1:1, by volume).
Negative-ion FAB MS was performed as described before (Miller-Podraza et al. 2004 ).
Helicobacter pylori strains
The following strains were used: CCUG 17874, CCUG 17875, and CCUG 26695 (from Culture Collection Göteborg University, Sweden); the BabA1A2-knocked out mutant derivative of CCUG 17875 (from Dr. Thomas Borén, Umeå University, Sweden); and the strain S-032 (obtained from a patient with duodenal ulcer at theÖrebro Medical Center,Örebro, Sweden). Growth of H. pylori cells was as previously described (MillerPodraza et al. 1996) .
TLC methods
Chromatogram binding assays using 35 S-labeled H. pylori cells were performed as described before (Miller-Podraza et al. 2004 , 2005 Johansson et al. 2005) . Silica gel HPTLC plates were from Merck, Germany (silica gel 60 on aluminum sheets).
